Skip to main content
Premium Trial:

Request an Annual Quote

Invitae, Passage Bio Collaborate on GM1 Genetic Testing, Clinical Trial Education

NEW YORK ─ Passage Bio and Invitae on Monday announced that they are collaborating to facilitate genetic testing and support early identification of GM1 gangliosidosis (GM1) through Invitae's Detect Lysosomal Storage Disorders (Detect LSDs) program.

The companies are also partnering to provide clinical trial information to clinicians and patients.

San Francisco-based Invitae's Detect LSDs program, available in the US and Canada, provides genetic testing and genetic counseling at no charge to patients to encourage earlier diagnosis of lysosomal storage disorders like GM1 and, as a result, earlier access to clinical trials, the firms said.

GM1 is a rare and often life-threatening monogenic recessive lysosomal storage disease caused by mutations in the GLB1 gene, which encodes lysosomal acid beta-galactosidase (B-gal).

"Early identification and intervention are crucial steps in providing effective treatment to patients with GM1, particularly in the infantile form where onset occurs within the first six months of a patient's life," Bruce Goldsmith, president and CEO of Philadelphia-based Passage Bio, said in a statement. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.